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Abstract
Objective: The study purposes were to describe the percentage of patients in one of four mood groups (i.e., neither
anxiety nor depression [NEITHER], only anxiety [ANX], only depression [DEP], both anxiety and depression
[BOTH]) and to evaluate how differences in mood states are related to pain, hope, and quality of life (QOL).
Methods: Oncology inpatients (n¼ 225) completed Brief Pain Inventory, Herth Hope Index (HHI), and the
European Organization for Research and Treatment of Cancer Core QOL Questionnaire-C30. Research nurses
completed Symptom Severity Checklist, Karnofsky Performance Status score, and medical record reviews. Data
were analyzed using w2, Kruskal-Wallis, one-way analyses of variance (ANOVAs), and analyses of covariance
(ANCOVA).
Results: Thirty-two percent of patients were categorized in the NEITHER group, 12% in the ANX group, 12% in
the DEP group, and 44% in the BOTH group. Younger patients and women were more likely to be in the BOTH
group. While only minimal differences were found among the mood groups on pain intensity scores, patients in
the NEITHER group in general, reported lower pain interference scores than those in the other three groups.
Significant differences were found in HHI scores between the patients in the NEITHER group and the BOTH
group. In addition, patients with both mood disorders reported significantly poorer QOL scores.
Conclusions: Because 44% of the patients had both anxiety and depression, clinicians need to evaluate patients
for the co-occurrence of these two symptoms, evaluate its impact on pain management, hope, and QOL, and
develop appropriate interventions to manage these symptoms.
Introduction
Anxiety and depression are common reactions to can-cer.1 Occurrence rates in patients with advanced
cancer for anxiety range from 13% to 79% and for de-
pression from 3% to 77%.2–6 While most studies have
evaluated these two mood disturbances separately,2,4
some evidence exists that depression and anxiety co-occurs
in the general population,7,8 and in oncology patients.4,9,10
In addition, in the general Norwegian population, co-
occurrence of anxiety and depression was more strongly
associated with somatic health problems than either anxi-
ety or depression.11
In a comprehensive review that examined the relationships
between chronic cancer pain and psychological distress,12 the
authors concluded that a significant positive correlation exists
between pain and psychological distress. However, most of
these studies examined only the independent associations
between anxiety and pain, or depression and pain.
Patients with more depression and anxiety have reported
less hope.13,14 For example, in a study of 80 hospitalized
Italian patients with cancer, significant negative correlations
were found between hope and anxiety (r¼0.50) and de-
pression (r¼0.58). This finding was confirmed in a recent
review15 that found oncology patients’ level of hope was re-
lated to physical and psychological factors.
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Finally, depression and anxiety have been associated with
lower levels of quality of life (QOL) in patients with advanced
cancer.2,3,5 Patients with both anxiety and depression re-
ported a higher frequency and intensity of symptoms when
compared with patients without anxiety or depression.2
The University of California, San Francisco’s Symptom
Management Theory (SMT)16 served as the conceptual
framework for this study. The SMT consists of three essential
concepts (i.e., symptom experience, symptom management
strategies, and symptom status outcomes). For the purposes
of this study, mood disturbance was the symptom experience
of interest. Hope was conceptualized to be a coping strategy
within the strategy domain. Finally, QOL was the outcome
of interest. Because cancer pain is associated with mood dis-
turbance in patients with advanced cancer17 and the SMT
suggests that multiple symptoms can be evaluated, the rela-
tionship between mood disturbance and pain was included
as part of the conceptual model in this study. While findings
from a limited number of studies suggest that depression and
anxiety appear to be significant problems in patients with
advanced cancer with pain17 and that anxiety and depression
are associated with patient’s level of hope and QOL,2,3,5,13–15
no studies were found that evaluated how depression or
anxiety or the co-occurrence of these two symptoms are re-
lated to pain, hope, and QOL in the same sample of patients.
Therefore, the purposes of this study in a sample of hospi-
talized patients with cancer pain were to describe the per-
centage of patients in one of four mood groups (i.e., neither
depression nor anxiety, only anxiety, only depression, or
both) and to evaluate how differences in mood status were
related to pain, hope, and QOL.
Methods
Sample and methods of data collection
This study is part of a large multicenter study, the Euro-
pean Pharmacogenetic Opioid Study.18 From a potential
sample of 1571 patients with cancer hospitalized at the Nor-
wegian Radium Hospital between December 2004 and June
2006, 342 met the initial screening criterion for the EPOS
study, namely that they would be on a regularly scheduled
opioid for their cancer pain for at least 3 days. In addition,
patients were included if they: were adults more than 18 years
of age; had a verified cancer diagnosis; provided a blood
sample; and gavewritten informed consent. The identification
of potential patients who met the study’s inclusion criteria
was performed systematically on all of the inpatient units.
Patients who met the study’s inclusion criteria were ap-
proached by the first author or one of two research nurses
who explained the purpose of the study.
A total of 225 patients were enrolled in this study. The
remaining 117 were not enrolled because they did not meet
one of the inclusion criteria (n¼ 34), were too ill (n¼ 33), re-
fused to participate (n¼ 48), or withdrew participation after
enrolment (n¼ 2). This study was approved by the Regional
Committee for Medical Research Ethics, Central-Norway and
the Norwegian Radium Hospital.
After enrollment, patients completed the Brief Pain In-
ventory (BPI), Herth Hope Index (HHI), and the European
Organization for Research and Treatment of Cancer Core
Quality of Life Questionnaire (EORTC QLQ-C30). If the pa-
tient was not able to complete the questionnaires indepen-
dently (n¼ 173), a research nurse read the items to these
patients and recorded their answers. Then the research nurse
assessed symptom severity by asking all of the patients to
respond to the Symptom Severity Checklist using a 4-point
Likert scale and rated the patient’s Karnofsky Performance
Status (KPS). Patients’ medical records were reviewed for
disease and treatment information (i.e., cancer diagnosis,
presence of metastasis, length of time since cancer diagnosis,
number of comorbidities). The research nurse followed a set of
interview guidelines during data collection. Data were mon-
itored on a regular basis by the third author (K.B.) to insure
data integrity.
Instruments
Demographic characteristics. Information was ob-
tained on age, gender, educational level, marital status, and
employment status.
Clinical characteristics. Patients’ performance status
was assessed using the KPS scale,19 which was rated by the
research nurse using a 0 (i.e., dead) to 100 (i.e., normal activ-
ity) scale. The KPS has satisfactory predictive and construct
validity20 and interrater reliability.21,22
Symptom severity (including anxiety and depression).
The observer-rated symptom severity checklist18,23 consists
of 17 symptoms (i.e., pain, fatigue, generalized weakness,
anxiety, anorexia, depression, constipation, poor sleep, dys-
pnea, focal weakness, nausea, confusion, vomiting, diarrhea,
itch, hallucinations, hiccups). The research nurses asked the
patients to rate each of these symptoms using a 4-point
Likert scale (i.e., none, mild, moderate, severe).
Pain characteristics. Pain in the last 24 hours was as-
sessed using theNorwegian version of the BPI-N.24 Part 1 of the
BPI consists of four single items on pain severity (i.e., pain now,
as well as least, average, and worst pain). Each item is rated on
a 0 (no pain) to 10 (theworst pain I can imagine) numeric rating
scale (NRS). Part 2 assesses the extent to which pain interferes
with seven aspects of function. Each item is rated on 0 to 10
NRSs. The BPI is valid across cultures and languages,24,25 is
sensitive to changes in pain intensity,26 and is simple to use.
Information on breakthrough pain (BTP) was obtained by
asking patients to indicate whether or not (i.e., yes=no re-
sponses) they had BTP elicited by movement, swallowing,
defecation, or urination.
Hope. Hope was measured using the Norwegian version
of the HHI.27 The HHI-N was selected because it is short
and easy to use.28 The HHI is based on the definition of
hope developed by Dufault and Martocchio.29 This 12-item
questionnaire measures various dimensions of hope using a
4-point Likert scale that ranges from strongly disagree (1) to
strongly agree (4). A total score can range from 12 to 48.28
Higher scores indicate higher levels of hope. Construct va-
lidity,28 divergent validity,30,31 internal consistency32 and
test–retest correlations28 were reported to be satisfactory in
different international samples.32–40 The Cronbach a for this
study was 0.76.
QOL. The EORTC QLQ-C30 (version 3.0)41,42 consists
of five function scales, seven symptom scales, a financial
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difficulties scale, and a global health status scale. The raw
scores were transformed linearly to a scale that ranges from 0
to 100 using the algorithm from the EORTCQLQ-C30 scoring
manual.43 Higher scores on the function scales and the global
health status scale indicate a better level of functioning and
overall QOL. In contrast, higher scores on the symptom scales
indicate more severe symptoms. The Norwegian version of
the EORTC QLQ-C30 has acceptable validity and reliabil-
ity.41,44 In this study, the Cronbach a for the three EORTC
QLQ-30 subscales that had more than 2 items (i.e., physical
functioning, emotional functioning, and fatigue) ranged from
0.80 to 0.81.
Statistical analyses
Data were analyzed using SPSS 15.0 (SPSS, Inc., Chicago,
Ill) and the a level was set at 0.05. Descriptive statistics
were calculated for the sample’s demographic and clinical
characteristics. The sample was divided into four mood
groups: those who had neither anxiety nor depression,
(none on both items [NEITHER]), only anxiety (mild,
moderate, or severe anxiety but none on depression
[ANX]), only depression (none on anxiety but mild, mod-
erate, or severe on depression [DEP]), or both anxiety and
depression (BOTH). In addition, patients were classified
into two groups based on whether the patients completed
the questionnaires themselves or were interviewed by the
research nurse. The percentage of patients in each of the
four mood status groups, as well as the demographic and
clinical characteristics of these two groups were compared
using w2, Mann-Whitney, and independent sample t-test
techniques.
w2, Kruskal-Wallis, and one-way analyses of variance
(ANOVAs) were used to evaluate for differences among the
four mood groups in demographic and clinical characteris-
tics. Based on these initial analyses, significant differences
were found in the age and the percentages of men and
women in the four mood groups. Based on reported gender
differences in anxiety,45 depression46 and pain,47,48 gender
and age were added as covariates with mood group as a
fixed factor in the subsequent analyses, using an analysis of
covariance (ANCOVA). If the overall ANOVA or Kruskal-
Wallis test was significant, pairwise contrasts were con-
ducted to determine where the differences were. The p value
of any of the six pairwise contrasts needed to be <0.008 in
order to be significant.
Table 1. Differences in Demographic and Clinical Characteristics among the Four Mood Groups
NEITHER (1)
n¼ 71 (31.6%)
ANX (2)
n¼ 27 (12.0%)
DEP (3)
n¼ 28 (12.4%)
BOTH (4)
n¼ 99 (44.0%)
Characteristics Mean SD Mean SD Mean SD Mean SD Statistics
Age (years) 64.1 (11.7 ) 55.7 (12.7) 62.6 (13.6) 59.0 (11.5) F¼ 4.36,
p¼< 0.01 1 > 2 & 4a
Number of comorbidities 0.9 (1.0) 0.9 (1.1) 1.1 (1.0) 1.2 (1.2) F¼ 1.62, p¼ 0.19
Karnofsky Performance Status 66.3 (15.6) 71.1 (9.3) 64.6 (13.5) 62.2 (17.0) F¼ 2.64, p¼ 0.05
Years since diagnosis 2.3 (3.8) 2.1 (4.6) 1.9 (2.4) 2.0 (3.3) F¼ 0.13, p¼ 0.94
% (N) % (N) % (N) % (N)
Gender
Male 62.0 (44) 40.7 (11) 42.9 (12) 40.4 (40) **K-W w2¼ 8.70,
p¼ 0.03 Male 1> 4a
Female 38.0 (27) 59.3 (16) 57.1 (16) 59.6 (59)
Marital status
Married 67.1 (47) 70.4 (19) 59.3 (16) 63.9 (60) K-W w2¼ 2.99, p¼ 0.81
Not married 18.6 (13) 22.2 (6) 22.2 (6) 22.5 (24)
Widow=widower 14.3 (10) 7.4 (2) 18.5 (5) 10.6 (10)
Employment status
Not work 97.1 (68) 92.6 (25) 96.3 (26) 97.8 (91) K-W w2¼ 1.91, p¼ 0.59
Work full-part-time 2.9 (2) 7.4 (2) 3.7 (1) 2.2 (2)
Education
Primary school 67.2 (47) 40.7 (11) 66.7 (18) 64.1 (59) K-W w2¼ 10.68, p¼ 0.10
Secondary school 15.7 (11) 14.8 (4) 7.4 (2) 16.3 (15)
College=University 17.1 (12) 44.5 (12) 25.9 (7) 19.6 (18)
Cancer diagnosis
Other 52.1 (37) 51.9 (14) 46.5 (13) 54.5 (54) K-W w2¼ 8.08, p¼ 0.78
Gastrointestinal 14.1 (10) 18.5 (5) 25.0 (7) 11.1 (11)
Female=reproductive 14.1 (10) 18.5 (5) 7.1 (2) 15.2 (15)
Prostate 12.7 (9) 3.7 (1) 7.1 (2) 9.1 (9)
Breast 7.0 (5) 7.4 (2) 14.3 (4) 10.1 (10)
Presence of metastatic disease
Yes 74.6 (53) 55.6 (15) 64.3 (18) 71.7 (71) K-W w2¼ 3.97, p¼ 0.27
No 25.4 (18) 44.4 (12) 35.7 (10) 28.3 (28)
aStatistically significant pairwise contrasts p< .008 (in bold).
**K-W¼Kruskal-Wallis.
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Results
Differences in the percentage of patients
in each mood status group, demographic
and clinical characteristics between patients
who completed the questionnaires themselves
(n¼ 50) or were interviewed (n¼ 173)
No significant differences were found in the percentage of
patients in each of the four mood groups based on how the
data were obtained. Patients who were interviewed had sig-
nificantly lower mean KPS scores (t¼2.45, p¼ 0.02), were
significantly older (t¼ 5.49, p< 0.001), had a higher average
number of comorbidities (t¼ 2.98, p< 0.01), and had less ed-
ucation (Mann-Whiteny Z¼4.92, p< 0.001) than those who
completed the questionnaires themselves.
Differences in demographic and clinical
characteristics among the mood groups
As shown in Table 1, 32% of the patients were categorized
in the NEITHER group, 12% in the ANX group, 12% in the
DEP group, and 44% in the BOTH group. No differences were
found among the four mood groups on any demographic or
clinical characteristics except for age and gender. Patients in
the BOTH and ANX groups were significantly younger than
patients in the NEITHER group. In addition, significantly
more men were in the NEITHER than in the BOTH group.
Differences in pain characteristics
among the mood groups
No significant differences were found among the four
mood groups on presence of BTP and the percent of pain
relief. However, as shown in Table 2, significant differences
were found among the four mood groups on two of the pain
intensity scores, the total interference score, as well as on all of
the pain interference items, except for work. After controlling
for age and gender, patients in the NEITHER group had sig-
nificantly lower least pain intensity scores than patients in the
BOTH group. In addition, both the NEITHER and the BOTH
groups reported significantly lower worst pain intensity
scores than the DEP group.
Table 2 summarizes differences in pain interference scores
among the four mood groups. In general, patients in the
NEITHER group reported lower pain interference scores than
the other three mood groups. In terms of the total interference
score, patients in the DEP and BOTH groups reported higher
scores than those in the NEITHER group. The NEITHER
group reported lower scores on interference with relations
with other people and interferencewith sleep than those in the
three other groups. As expected, the NEITHER group re-
ported significantly lower mood interference scores than the
three other mood groups. Finally, patients in the NEITHER
group rated pain interference with enjoyment of life signifi-
cantly lower than patients in the DEP or BOTH groups.
Table 2. Differences in Pain Characteristics among the Four Mood Groups
NEITHER (1)
n¼ 71
ANX (2)
n¼ 27
DEP (3)
n¼ 28
BOTH (4)
n¼ 99
Characteristics (%) N (%) N (%) N (%) N Statistics
Percentage of patients with
breakthrough pain
74.6 (53) 76.9 (20) 96.4 (27) 80.8 (80) K-W w2¼ 6.26,
p¼ 0.10
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Pain now 2.2 (2.0) 2.8 (1.9) 2.8 (2.1) 3.0 (2.5) F¼ 1.09, p¼ 0.36
Least pain 1.4 (1.4) 1.7 (2.3) 2.0 (1.5) 2.2 (1.8) F¼ 3.23, p¼ 0.02;
1 < 4a
Average pain 3.8 (2.4) 4.0 (2.5) 4.5 (2.0) 4.7 (2.4) F¼ 1.84, p¼ 0.14
Worst pain 4.5 (2.7) 5.1 (2.2) 6.5 (2.8) 5.0 (2.5) F¼ 3.83, p¼ 0.01;
1 & 4< 3a
Percent of pain relief 72.5 (24.6) 67.7 (22.1) 68.9 (22.7) 66.0 (24.9) F¼ 1.27, p¼ 0.29
Total pain interference score 3.0 (2.1) 4.3 (2.2) 5.0 (2.4) 5.1 (2.3) F¼ 11.69, p< 0.001;
1 < 3 & 4a
Pain interference daily activity 4.7 (3.6) 5.6 (3.0) 6.5 (3.0) 6.2 (3.1) F¼ 2.93, p¼ 0.04b
Pain interference mood 1.8 (2.4) 4.0 (2.8) 5.1 (2.6) 4.8 (3.2) F¼ 16.03, p< 0.001;
1 < 2, 3 & 4a
Pain interference ability walk 3.5 (3.8) 3.1 (3.1) 5.2 (3.9) 4.8 (3.5) F¼ 3.13, p¼ 0.03b
Pain interference work 5.5 (4.0) 6.1 (3.3) 6.7 (3.9) 7.3 (3.4) F¼ 2.51, p¼ 0.06
Pain interference relations to other 1.3 (2.2) 3.6 (2.7) 3.3 (3.0) 3.9 (3.3) F¼ 9.78, p< 0.001;
1 < 2,3 & 4b
Pain interference sleep 2.1 (2.9) 4.7 (3.3) 4.5 (3.4) 3.8 (3.3) F¼ 5.14, p< 0.01;
1 < 2,3 & 4a
Pain interference enjoyment of life 2.0 (2.7) 3.3 (2.8) 4.4 (3.3) 5.1 (3.2) F¼ 13.92, p< 0.001;
1 < 3 & 4a
aStatistically significant pairwise contrasts p< .008 (in bold).
bNo statistically significant pairwise contrasts.
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Differences in hope among the mood groups
As shown in Figure 1, a significant difference in total HHI
scores was found among the four groups (F¼ 3.98, p¼ 0.01).
Patients in the NEITHER group had higher HHI scores than
those in the BOTH group (39.2 [ 3.8] versus 37.2 [ 4.6]).
Differences in QOL among the mood groups
As shown in Table 3, after controlling for age and gender,
patients in the NEITHER group reported a significantly better
global health status than patients in the BOTH group. How-
ever, no differences where found among the four mood
groups on physical function. Patients in the ANX group re-
ported higher role function scores than patients in the BOTH
group. As expected, patients in the NEITHER group reported
higher emotional function than those in the other three
groups. In addition, patients in the ANX group reported
higher emotional functioning compared to the BOTH group.
Discussion
To our knowledge, this study is the first to examine the
relationships between pain, hope, and QOL among hospital-
ized cancer patients with pain, whowere categorized into one
of four mood groups. In this sample of patients on opioids, in
which 70% had advanced disease, the overall occurrence of
one or both mood disturbances was 68%. That 12% reported
anxiety, 12% reported depression, and as many as 44% re-
ported anxiety and depression is consistent with previous
studies of patients with advanced cancer that used simple
single- or multiple-item scales to evaluate mood distur-
bance.4,23
The finding that 44% of the patients in this study were
categorized as having both anxiety and depression is consis-
tent with two studies of patients with advanced cancer that
reported co-occurrence rates of 26%2 to 60%.4 Findings from
these three studies suggest that clinicians need to evaluate
patients with advanced cancer with pain for the co-occurrence
of these two mood disturbances and develop appropriate
treatment strategies.
The lack of differences in BPI pain intensity scores may be
related to the fact that all of the patients had pain and were
using opioid analgesics. However, the largest difference in
pain intensity scores was between the DEP group and the
NEITHER group on ratings of worst pain. This difference
equates with a large effect size (i.e., d¼ 0.77, where d is the
difference between the two means in standard deviation
units),49 which suggests a clinically meaningful difference in
worst pain intensity scores.50
The findings of lower interference scores in the NEITHER
group compared to the other three groups suggest that mood
disturbances in patients with cancer pain may bemore closely
associated with pain interference than with pain intensity.
This hypothesis is supported by a Taiwanese study32 that
found higher positive correlations between mood distur-
bances and pain interference (r¼ 0.53) than between mood
disturbances and pain intensity (r¼ 0.26). The lack of differ-
ences among the mood groups on interference with work in
this sample, may be related to the fact that these patients were
hospitalized and not working.
In this sample of hospitalized cancer patients in pain, those
in the BOTH group had significantly lower total HHI scores
than those in the NEITHER group (i.e., d¼ 0.47). Although
the difference in absolute scores is relatively small (i.e., 2
units), the moderate effect size suggests a clinically mean-
ingful difference.51,52 In addition, this finding is consistent
with a previous study of hospitalized Italian patients with
cancer13 that reported that hope was negatively correlated
with anxiety and depression.
FIG. 1. Differences in total Herth Hope Index (HHI) scores
among the four mood groups (*Significantly higher total
HHI scores found in the NEITHER group compared to the
BOTH group ( p¼ 0.01).)
Table 3. Differences in European Organization for Research and Treatment of Cancer Core Quality
of Life Questionnaire (EORTC QLQ-C30) Scores among the Four Mood Groups
NEITHER (1)
n¼ 71
ANX (2)
n¼ 27
DEP (3)
n¼ 28
BOTH (4)
n¼ 99
EORTC QLQ-C30 Mean (SD) Mean (SD) Mean (SD) Mean (SD) Statistics
Global health status 48.0 (24.9) 41.7 (21.6) 36.3 (24.1) 30.9 (24.6) F¼ 6.15, p< 0.001; 1> 4a
Physical function 42.6 (27.5) 45.9 (21.3) 42.4 (23.1) 37.3 (24.1) F¼ 1.08, p¼ 0.36
Role function 27.0 (31.5) 35.8 (34.2) 19.0 (24.3) 15.1 (22.7) F¼ 5.15, p< 0.01; 2> 4a
Emotional function 85.0 (16.3) 66.7 (19.3) 60.7 (25.2) 51.6 (24.4) F¼ 30.16, p< 0.001;
1> 2,3 & 4a; 2> 4a
Cognitive function 74.4 (23.0) 65.4 (28.1) 61.9 (27.9) 52.7 (29.4) F¼ 7.93, p< 0.01; 1> 4a
Social function 53.1 (33.6) 44.4 (29.2) 39.3 (24.5) 33.7 (29.4) F¼ 4.03, p< 0.01; 1> 4a
aStatistically significant pairwise contrasts p< 0.008 (in bold).
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Consistent with previous reports that evaluated depression
and anxiety separately,3,5 mood disturbance in cancer patients
with pain was associated with a decrease in QOL. However,
in this study that categorized patients with cancer with pain
into one of four mood groups, several clinically significant
differences in their QOL were found. First, clinically mean-
ingful differences were found among the four mood groups
on all of the functional scales except for physical function.
Specifically, differences were found between patients in the
NEITHER group compared to those in the BOTH group on
emotional functioning (i.e., d¼ 1.29), cognitive functioning
(i.e., d¼ 0.76), and social functioning (i.e., d¼ 0.62). These
differences equate with changes in the moderate (i.e., a dif-
ference from 10 to 20) to very much (i.e., a difference of >20)
range.53 In addition, the difference in the global health status
score between these two extreme groups reflects a medium
effect size (i.e., d¼ 68).
A number of limitations of this study need to be acknowl-
edged. First, the causal relationships between anxiety, de-
pression and pain, hope, and QOL could not be determined
due to the study’s cross-sectional design. Future research
needs to examine changes in these variables over time, as well
as test the relationships among the variables that were hy-
pothesized in our introduction. Although the overall sample
size was relatively large, the distribution of the mood groups
resulted in two groups with relatively small sample sizes.
Therefore, findings from this study should be replicated in a
larger sample to determine if these occurrence rates are stable
and if additional differences exist among the mood groups.
The differences in how the data were collected may influ-
ence the validity of the study findings. However, no differ-
ences were found in the percentage of patients in each mood
status group based on whether patients completed the ques-
tionnaires themselves or were interviewed. In addition, the
significant differences in a number of characteristics between
those who were interviewed and those who completed the
questionnaires themselves explain why they needed help.
The oldest patients with the poorest functional status were the
ones who needed help. This finding is consistent with Wilson
and colleagues,54 who noted that self-administered scales
may have limited applicability for some older adults who are
terminally ill. Because the patients were fairly ill, respondent
burden was a major concern for the researchers. Therefore, as
have others,4 in order to include a representative sample of
patients with advanced cancer with pain, patients were af-
forded the opportunity to provide written or verbal responses
to the study questionnaires.
The use of a single-item questionnaire to measure anxiety
and depression is a limitation of this study. However, in a
recent review of the measurement of psychological distress in
palliative care,55 Kelly and colleagues reported that assess-
ment measures like the Edmonton Symptom Assessment
Scale, play an important role in clinical research. In addition,
Hotopf and colleagues,56 noted that a single-item question-
naire has obvious advantages in palliative care populations.
Finally, Thekkumpurath and colleagues57 concluded in a
systematic review that unidimensional scales appear to per-
form equally well compared to the longer versions in pallia-
tive care. Equally important, Chochinov58 noted that making
a diagnosis of depression in cancer patients is challenging and
that single-item screening proved to be as diagnostically
useful as much more complicated self-report scales.
Despite these limitations, findings from this study suggest
that patients’ level and type of mood disturbance are related
to a number of aspects of pain, hope, and QOL. In light of the
paucity of research on the co-occurrence of anxiety and de-
pression in cancer patients, and their relationship to pain,
hope and QOL, these findings warrant replication in larger
cross sectional as well as longitudinal studies.
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